Atara Biotherapeutics is pioneering immunotherapies for life threatening and debilitating diseases. Our allogeneic cytotoxic T lymphocyte (CTL) immunotherapy platform is built on ground breaking research and complimentary technologies that precisely target and activate CTLs to treat a variety of diseases.

We have a late-stage development pipeline with clinical and pre clinical product candidates. Along with our partners, we have generated clinical data supporting the therapeutic potential of our CTL product candidates in certain hematologic malignancies, solid tumors, autoimmune diseases and severe viral infections.

Our lead program, ATA129 is poised to enter Phase 3 trials for two indications and has been granted:

  • Orphan and breakthrough designation from FDA,
  • Orphan and advanced therapy medicinal product (ATMP) designation from EMA, and
  • Access to priority medicines regulatory support (PRIME) for the lead indication from EMA.

The benefits of our allogeneic cytotoxic T lymphocyte (CTL) immunotherapy platform are exhibited in our product candidates:

  • Off-the-shelf, ready to utilize therapies
  • Efficient management of therapeutic inventory
  • Precision targeting
    • Our core technology creates CTLs broadly targeted to recognize EBV and CMV viral antigens, and certain tumor associated antigens such as WT1
    • Our next generation CTL technology uses selective antigen targeting to create CTLs targeted for specific EBV, CMV, HPV, and BK viral antigens. This selective antigen targeting is being applied to development programs where we believe it may provide therapeutic advantages.
    • Prompt treatment – from the identification of need, we can deliver a therapeutic T-cell line for a patient in ~3-5 days.
    • Compelling safety profile
      • No lymphodepletion required before treatment
      • For ATA129, in 126 patients treated there were:
        • Nine possibly related serious adverse events, or SAEs
        • No infusion related toxicities
        • No evidence of cytokine release syndrome
        • One case of treatment-related grade 1 graft versus host disease, or GvHD, which resolved with topical treatment